Kiniksa Pharmaceuticals Ltd (KNSA)
17.66
+0.05
(+0.28%)
USD |
NASDAQ |
Apr 26, 10:09
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.253B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 59.08% |
Valuation | |
PE Ratio | 160.55 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.247 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 83.06% |
Profile
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. |
URL | https://www.kiniksa.com |
Investor Relations URL | https://investors.kiniksa.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | Jul. 25, 2024 (est.) |
Last Earnings Release | Apr. 23, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. |
URL | https://www.kiniksa.com |
Investor Relations URL | https://investors.kiniksa.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | Jul. 25, 2024 (est.) |
Last Earnings Release | Apr. 23, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |